Literature DB >> 837961

Paradoxical potassium excretion in response to aldosterone antagonists.

L E Ramsay, I R Harrison, J R Shelton, M J Tidd.   

Abstract

The activity of two aldosterone antagonists in reversing the urinary electrolyte changes induced by the mineralocorticoid fludrocortisone was examined in healthy subjects. Between 2-10 h after treatment there were dose-related increases in sodium excretion and the urine log 10 Na/K ratio, but no significant changes in urine volume, potassium concentration, or potassium excretion. Between 12-16 h after treatment there were dose-related increases in urine sodium excretion and the log 10 Na/K ratio. Unexpectedly, there were significant dose-related increases in potassium excretion despite significant dose-related reductions in urinary potassium concentration. The paradoxical increases in potassium excretion were attributed to dose-related increases in urine volume in the same period. These observations may explain the increased potassium excretion occasionally observed during clinical use of aldosterone antagonists and suggest that potassium excretion in man is influenced by the urine flow rate.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837961     DOI: 10.1007/BF00562899

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

Review 1.  ALDOSTERONE AND ITS ANTAGONISTS.

Authors:  E J ROSS
Journal:  Clin Pharmacol Ther       Date:  1965 Jan-Feb       Impact factor: 6.875

2.  Human assay of electrolyte-active steroids and their antagonists.

Authors:  E J ROSS
Journal:  Clin Sci       Date:  1962-10       Impact factor: 6.124

3.  Metabolic studies on the effects of sprinolacton.

Authors:  H JICK; R S MORRISON; E W MOORE; T C CHALMERS
Journal:  Metabolism       Date:  1963-05       Impact factor: 8.694

4.  Spironolactone in hypertensive patients. Oligemic and antihypertensive effects.

Authors:  A J GEORGOPOULOS; H DUSTAN; I H PAGE
Journal:  Arch Intern Med       Date:  1961-09

5.  [Study of the metabolic effects of the spirolactone SC 9420 in man].

Authors:  J D ROMANI; A KELLER
Journal:  Ann Endocrinol (Paris)       Date:  1961 May-Jun       Impact factor: 2.478

6.  The action of hydroflumethiazide in relation to adrenal steroids and potassium loss.

Authors:  C J EDMONDS; G M WILSON
Journal:  Lancet       Date:  1960-03-05       Impact factor: 79.321

7.  Renal mechanisms for excretion of potassium.

Authors:  R W BERLINER; T J KENNEDY; J G HILTON
Journal:  Am J Physiol       Date:  1950-08-01

8.  Effect of amiloride, ouabain, and furosemide on distal tubular function in the rat.

Authors:  C G Duarte; F Chomety; G Giebisch
Journal:  Am J Physiol       Date:  1971-08

9.  Bioassay of adrenal cortical steroids on the basis of electrolyte excretion by rats: effects of 11-desoxy and 11-oxy-steroids.

Authors:  B B JOHNSON
Journal:  Endocrinology       Date:  1954-02       Impact factor: 4.736

10.  Characteristics of the relationship between the flow rate of tubular fluid and potassium transport in the distal tubule of the rat.

Authors:  R T Kunau; H L Webb; S C Borman
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  2 in total

1.  Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.

Authors:  G T McInnes; J R Shelton; I R Harrison; R M Perkins; R F Palmer
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

2.  Drug attributed alterations in potassium handling in congestive cardiac failure.

Authors:  D H Lawson; P C O'Connor; H Jick
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.